

Supporting Information for

**Self-Assembled Daunorubicin/Epigallocatechin Gallate
Nanocomplex for Synergistic Reversal of Drug Resistance in
Leukemia**

Ki Hyun Bae ¹, Fritz Lai ², Betul Oruc ¹, Motomi Osato ³, Qingfeng Chen ², and Motoichi Kurisawa ^{1,4,*}

¹Institute of Bioengineering and Bioimaging, 31 Biopolis Way, The Nanos, Singapore 138669; khbae@ibb.a-star.edu.sg (K.H.B.); betulaltin@alumni.sabanciuniv.edu (B.O.)

²Institute of Molecular and Cell Biology, 61 Biopolis Drive, The Proteos, Singapore 138673; sclai@imcb.a-star.edu.sg (F.L.); qchen@imcb.a-star.edu.sg (Q.C.)

³Cancer Science Institute of Singapore, National University of Singapore, 14 Medical Drive, Singapore 117599.; csimo@nus.edu.sg (M.O.)

⁴School of Materials Science, Japan Advanced Institute of Science and Technology, 1-1 Asahidai, Nomi, Ishikawa 923-1292, Japan

*Correspondence: kurisawa@jaist.ac.jp




Figure S1. Representative photograph of Dauno-MNC (left) and HA/DNR complex (right).




Figure S2. Fluorescence emission spectra ($\lambda_{\text{ex}}=480$ nm) of DNR solution (5 pM) mixed with various concentrations of HA.




Figure S3. Cytotoxicity of Dauno-MNC, HA-EGCG and EGCG against HL-60/MX2 cells as a function of EGCG unit concentration. Mean $\pm$ SD ($n = 4$).




Figure S4. Flow cytometric detection of CD44 in HL-60 and HL-60/MX2 cells labeled without (left panel) or with FITC-tagged anti-CD44 antibody (right panel).